Want to see FR:ALNEV full AI Analyst Report?
Top Page
Neovacs SA
(ALNEV)
Select Model
Select Model
Rating:42Neutral
Price Target:
€0.40
▲(3930.00% Upside)
Action:Reiterated
Date:08/27/26
The score is pulled down primarily by weak financial performance (ongoing losses, negative margins, and continued cash burn) and very bearish technical momentum (deeply negative MACD and very low RSI). Low leverage provides some balance-sheet resilience, but valuation remains unattractive due to unprofitability and lack of a dividend signal.
Positive Factors
Low Leverage
Very low leverage reduces refinancing pressure and preserves flexibility to fund research or restructure operations. This is only a relative strength: it does not offset losses, but it gives the company more balance-sheet capacity than a highly indebted biotech.
Negative Factors
Sharp Revenue Decline
Revenue fell about 44% in 2025 after inconsistent sales across prior years, signaling limited commercial scale. Sustained revenue weakness makes it harder to absorb fixed R&D costs and increases dependence on future partnerships, milestones, or financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage reduces refinancing pressure and preserves flexibility to fund research or restructure operations. This is only a relative strength: it does not offset losses, but it gives the company more balance-sheet capacity than a highly indebted biotech.
Read all positive factors
Neovacs SA (ALNEV) vs. iShares MSCI France ETF (EWQ)
Market Cap
€47.72K
Dividend YieldN/A
Average Volume (3M)50.74K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue Growth-44.46%
EPS Growth100.00%
CountryFR
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding159,064
10 Day Avg. Volume45,632
30 Day Avg. Volume50,740
Financial Highlights & Ratios
PEG Ratio6.69
Price to Book (P/B)180.66
Price to Sales (P/S)20138.85
P/FCF Ratio-646.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neovacs SA Business Overview & Revenue Model
Company Description
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages it...
How the Company Makes Money
Neovacs’ business model is primarily biotechnology R&D-driven. The company would be expected to generate revenue through (1) out-licensing or co-development agreements for its Kinoid platform and/or individual drug candidates, typically structured...
Neovacs SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 161.78K | 366.35K | 533.41K | 1.11K | 22.59K |
| Gross Profit | -4.52M | 42.42K | -6.75M | -6.26M | -7.60M |
| EBITDA | -5.24M | -6.61M | -8.45M | -3.61M | -10.38M |
| Net Income | -4.90M | -32.91M | -8.74M | -3.55M | -11.84M |
Balance Sheet | |||||
| Total Assets | 22.14M | 22.07M | 47.53M | 49.28M | 48.55M |
| Cash, Cash Equivalents and Short-Term Investments | 571.79K | 435.45K | 887.09K | 6.76M | 33.09M |
| Total Debt | 537.20K | 230.37K | 650.59K | 1.20M | 1.03M |
| Total Liabilities | 4.10M | 4.01M | 3.71M | 5.05M | 4.65M |
| Stockholders Equity | 18.03M | 18.06M | 43.82M | 44.23M | 43.90M |
Cash Flow | |||||
| Free Cash Flow | -5.04M | -3.68M | -2.12M | -4.60M | -10.26M |
| Operating Cash Flow | -5.03M | -3.60M | -1.91M | -4.45M | -9.91M |
| Investing Cash Flow | -446.17K | 1.45M | -11.08M | -31.56M | -18.81M |
| Financing Cash Flow | 5.62M | 1.70M | 6.79M | 9.99M | 51.75M |
Neovacs SA Technical Analysis
Negative
0.01
Price Trends
0.74
Negative
156.84
Negative
Market Momentum
-2.97
Negative
20.93
Positive
14.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALNEV, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.74, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -2.97 indicates Negative momentum. The RSI at 20.93 is Positive, neither overbought nor oversold. The STOCH value of 14.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALNEV.
Neovacs SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €8.85B | -20.97 | -165.19% | ― | ― | ― | |
47 Neutral | €245.16M | -3.39 | -63.53% | ― | 291.43% | 12.24% | |
47 Neutral | €547.70M | -3.21 | -152.15% | ― | -27.19% | -117.39% | |
43 Neutral | €659.46M | -3.12 | -119.47% | ― | ― | 41.33% | |
43 Neutral | €63.71M | -1.60 | -96.73% | ― | -96.25% | -197.89% | |
42 Neutral | €47.72K | -2.31 | -27.13% | ― | -44.46% | 100.00% |
* Healthcare Sector Average
FR:ALNEV
Neovacs SA
0.30
-3,299.70
-99.99%
FR:ABVX
Abivax SA
101.30
29.60
41.28%
FR:DBV
DBV Technologies
2.10
0.44
26.84%
FR:TNG
Transgene
0.88
-0.27
-23.72%
FR:VLA
Valneva
2.89
-0.93
-24.44%
FR:OSE
OSE Immunotherapeutics SA
2.71
-3.24
-54.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.